PH Health Limited v. ARS Pharmaceuticals: Epinephrine Nasal Spray Patent Case Dismissed
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | PH Health Limited v. ARS Pharmaceuticals Operations, Inc. |
| Case Number | 1:26-cv-00184 (Fed. Cir.) |
| Court | District of Delaware |
| Duration | Feb 19, 2026 – Feb 27, 2026 8 days |
| Outcome | Voluntary Dismissal without Prejudice |
| Patents at Issue | |
| Accused Products | Neffy® (epinephrine nasal spray) |
Case Overview
The Parties
⚖️ Plaintiff
Plaintiff asserting patent rights in epinephrine formulation and delivery technology. Co-plaintiff Par Health USA, LLC suggests a coordinated IP holding/licensing structure.
🛡️ Defendant
Developer of Neffy®, an intranasal epinephrine spray for anaphylaxis. Leads a rapidly evolving segment of the allergy and emergency medicine market.
Patents at Issue
This lawsuit involved four U.S. patents covering technology in the epinephrine nasal spray and intranasal drug delivery space, reflecting a layered prosecution strategy to maintain forward-looking coverage as the field matured.
- • U.S. Patent No. 10,130,592 B2 (App. No. 14/863,112)
- • U.S. Patent No. 9,119,876 B1 (App. No. 14/657,990)
- • U.S. Patent No. 12,280,024 B2 (App. No. 18/477,161)
- • U.S. Patent No. 9,295,657 B1 (App. No. 14/818,121)
Developing a nasal drug delivery product?
Check if your formulation or device might infringe these or related patents before launch.
Litigation Timeline & Procedural History
The case was filed in the District of Delaware under Case No. 1:26-cv-00184 and presided over by Judge Maryellen Noreika. Delaware remains the preferred jurisdiction for pharmaceutical patent litigation due to its experienced bench and predictable procedures.
| Milestone | Date |
| Complaint Filed | February 19, 2026 |
| Voluntary Dismissal Filed | February 27, 2026 |
| Case Closed | February 27, 2026 |
The extraordinary brevity of this action, closing in just 8 calendar days, strongly suggests the dismissal was strategic rather than resulting from any judicial ruling on the merits.
The Verdict & Legal Analysis
Outcome
Pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(i), plaintiffs PH Health Limited and Par Health USA, LLC voluntarily dismissed the action without prejudice. Under this rule, a plaintiff may dismiss an action without a court order before the opposing party has served an answer or motion for summary judgment, preserving the right to refile. No damages were awarded or injunctive relief granted.
Verdict Cause Analysis
No substantive judicial analysis of the asserted patents was rendered given the pre-answer dismissal. The rapid voluntary dismissal is a pattern that experienced practitioners will recognize as a strategic move. Possible explanations include pre-filing settlement negotiations that concluded post-filing, a tactical filing to establish a priority date, or a reassessment of claim mapping to the accused product.
Legal Significance
This case generates no binding precedent and no claim construction rulings. Its significance lies primarily in what it signals — not in what it decided. The assertion of a four-patent portfolio, including a relatively recent patent (U.S. 12,280,024 B2), against Neffy® confirms that intellectual property competition around intranasal epinephrine delivery technology remains active and contested.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in pharmaceutical nasal drug delivery. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all related patents in the epinephrine nasal spray space
- See which companies are most active in nasal drug delivery IP
- Understand patent claim strategies in this sector
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Epinephrine nasal spray formulation
4 Patents Asserted
Against Neffy® platform
Strategic Dismissal
Preserves future claims
✅ Key Takeaways
Rule 41(a)(1)(A)(i) dismissals without prejudice preserve all future claims and carry no res judicata effect.
Search related case law →Delaware District Court remains the strategic forum of choice for pharmaceutical patent disputes.
Explore precedents →The four-patent portfolio structure signals a sophisticated, layered assertion strategy likely to resurface.
Analyze patent families →Frequently Asked Questions
Four U.S. patents were asserted: U.S. 10,130,592 B2; U.S. 9,119,876 B1; U.S. 12,280,024 B2; and U.S. 9,295,657 B1, all relating to epinephrine nasal spray technology.
Plaintiff voluntarily dismissed under Fed. R. Civ. P. 41(a)(1)(A)(i) before any responsive pleading was filed — a dismissal requiring no court order and preserving the right to refile.
The without-prejudice dismissal keeps all claims alive. Companies in the nasal epinephrine space should anticipate potential refiling and maintain current FTO and IPR readiness strategies.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- District of Delaware — Case 1:26-cv-00184
- Cornell Legal Information Institute — Fed. R. Civ. P. 41
- U.S. Patent and Trademark Office — Patent Search
- FDA — Neffy® Approval Announcement
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.